Increased Risk for Cardiovascular Events in Patients with Diabetic Kidney Disease and Non-Alcoholic Fatty Liver Disease

被引:11
|
作者
Chinnadurai, Rajkumar [1 ]
Chrysochou, Constantina [1 ]
Kalra, Philip A. [1 ]
机构
[1] Salford Royal NHS Fdn Trust, Dept Renal Med, Salford M6 8HD, Lancs, England
关键词
Non-alcoholic fatty liver disease; Diabetic kidney disease; Cardiovascular disease; Mortality; METABOLIC SYNDROME; NAFLD; STEATOSIS;
D O I
10.1159/000493472
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background/Aims: Non-alcoholic fatty liver disease (NAFLD) is recognised to be a strong risk factor for causing cardiovascular disease (CVD) and chronic kidney disease (CKD), independent of the presence of diabetes mellitus. The association of NAFLD with outcomes in patients with diabetic kidney disease (DKD) has been variably reported. This study aimed to investigate the association of NAFLD with cardiovascular, renal outcomes and mortality in patients with advanced DKD (CKD 3-5, not on dialysis). Methods: This observational study was carried out on 192 patients with DKD within a cohort of 2,974 non-dialysis CKD patients, who had an ultrasound (US) of their liver done between January 2000 and end of December 2014. From these 192 patients, 149 patients (NAFLD 48 and normal US 101) were included for comparative analysis, as they had complete datasets. Patient demographics, comorbidities and blood results were collected at study baseline. Follow-up data on non-fatal cardiovascular events (NFCVE), mortality and serial estimated glomerular filtration rate (eGFR) was gathered until study end point. Cox-regression analysis was used to study the association of NAFLD with NFCVE and mortality, and linear regression analysis was used for the estimation of renal progression. Results: Median follow-up time was 69 months, similar in both groups (p = 0.09). Median eGFR was 31.6 mL/min/1.73 m(2), with a median urine protein creatinine ratio of 46 g/mol. A total of 20 (41.7%) NFCVE were recorded in the NAFLD group compared to 14 (13.9%) in the normal US group. Multivariable Cox-regression analysis showed NAFLD as an independent risk factor (hazard ratio 2.95; 95% CI 1.31-6.60; p = 0.01) for NFCVE even after including all cardiovascular risks parameters that were significant in the univariable model. There was no significant difference in survival between the 2 groups over the follow-up period (logrank test, p = 0.76). The overall rate of decline in eGFR was 3.46 mL/min/1.73 m(2)/year and this was not observed to be different between the groups (p = 0.65). Conclusion: In our cohort of patients with advanced DKD, NAFLD showed a strong independent association with cardiovascular outcomes. Further prospective studies are warranted to strengthen these associations and plan a strategy for screening NAFLD in this high-risk group. (c) 2018 S. Karger AG, Basel
引用
收藏
页码:24 / 30
页数:7
相关论文
共 50 条
  • [21] Non-alcoholic fatty liver disease and cardiovascular risk: an update
    Mullish, Benjamin H.
    Forlano, Roberta
    Manousou, Pinelopi
    Mikhailidis, Dimitri P.
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 12 (12) : 1175 - 1177
  • [22] Cardiovascular Risk Factors in Non-Alcoholic Fatty Liver Disease
    Hagstrom, Hannes
    Nasr, Patrik
    Ekstedt, Mattias
    Hammar, Ulf
    Stal, Per
    Hultcrantz, Rolf W.
    Kechagias, Stergios
    [J]. HEPATOLOGY, 2018, 68 : 950A - 950A
  • [23] Non-Alcoholic Fatty Liver Disease (NAFLD) Is Associated with an Increased Risk for Diabetic Nephropathy
    Higa, Mariko
    Yamashita, Kaoru
    Iga, Ryo
    Yoshifuji, Ayumi
    Yoshida, Eiko
    Ichijo, Takamasa
    Ouchi, Hiromi
    Inokuchi, Toshiki
    [J]. DIABETES, 2011, 60 : A164 - A164
  • [24] Cardiovascular risk factors in non-alcoholic fatty liver disease
    Hagstrom, Hannes
    Nasr, Patrik
    Ekstedt, Mattias
    Hammar, Ulf
    Stal, Per
    Askling, Johan
    Hultcrantz, Rolf
    Kechagias, Stergios
    [J]. LIVER INTERNATIONAL, 2019, 39 (01) : 197 - 204
  • [25] Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease
    Park, Jung Gil
    Jung, Jinho
    Verma, Kritin K.
    Kang, Min Kyu
    Madamba, Egbert
    Lopez, Scarlett
    Qas Yonan, Aed
    Liu, Amy
    Bettencourt, Ricki
    Sirlin, Claude
    Loomba, Rohit
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (09) : 1030 - 1037
  • [26] Non-alcoholic fatty liver disease and cardiovascular risk factors in obese patients
    Melnichenko, G.
    Butrova, S.
    Eliseeva, A.
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2008, 32 : S143 - S143
  • [27] THE CIRCULATING ISOMIR-OME OF INCREASED CARDIOVASCULAR RISK IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
    Makarenkov, Nataly
    Yoel, Uri
    Haim, Yulia
    Bhandarkar, Nikhil S.
    Shalev, Aryeh
    Shelef, Ilan
    Liberty, Idit F.
    Ben-Arie, Gal
    Yardeni, David
    Rudich, Assaf
    Veksler-Lublinsky, Isana
    Etzion, Ohad
    [J]. HEPATOLOGY, 2022, 76 : S655 - S655
  • [28] Remnant Cholesterol Predicts Major Cardiovascular Events in Cardiovascular Disease Patients with Non-Alcoholic Fatty Liver Disease
    Larcher, Barbara
    Mader, Arthur
    Sprenger, Lukas
    Vonbank, Alexander
    Maechler, Maximilian
    Plattner, Thomas
    Leiherer, Andreas
    Muendlein, Axel
    Drexel, Heinz
    Saely, Christoph
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 : S774 - S774
  • [29] Liver Fibrosis: An Independent Risk Factor for Cardiovascular Disease in Patients with Non-alcoholic Fatty Liver Disease
    McNally, Bridgette B.
    Fallon, Michael
    Rangan, Pooja
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S548 - S549
  • [30] Liver disease severity and risk of kidney damage in patients with non-alcoholic fatty liver disease (NAFLD)
    Agrawal, Saurabh
    Lopez, Rocio
    Omo, Jason T.
    Conjeevaram, Hari S.
    [J]. GASTROENTEROLOGY, 2008, 134 (04) : A784 - A784